Most women have some nausea or vomiting, or “morning sickness”, during the first trimester of pregnancy. Some women, however, have a more severe and persistent pattern of nausea and vomiting called hyperemesis gravidarum (HG). [...]
While many women with postpartum depression (PPD) have had previous episodes of major depression and will go on to have other episodes of depression outside of the postpartum period, many have questioned whether postpartum depression [...]
While we have heard a lot about brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant – SAGE 217 or zuranolone – has been [...]
Zuranolone or SAGE-217 is similar to brexanolone (marketed as Zulresso), the medication which was FDA-approved for the treatment of postpartum depression. Zuranolone is a neurosteroid, an analogue of allopregnanolone, which is a positive allosteric [...]
Interpersonal therapy (IPT) has been shown to be effective for the treatment of postpartum depression. Typically this treatment is delivered in person; however given limited access to specialized providers, recent research has explored the [...]
Transcranial magnetic stimulation (TMS), an FDA approved treatment for major depression, is a noninvasive procedure which uses magnetic fields to stimulate specific areas of the brain. It is not commonly used as a first [...]
Many professional organizations, including the American Academy of Pediatrics, have pushed for a greater focus on maternal mental health as a means of improving outcomes in children and recommend universal screening for depression during [...]
While we have been talking about using brexanolone, marketed by Sage Therapeutics as Zulresso, for the treatment of postpartum depression, an oral version of this novel antidepressant - SAGE 217 or zuranolone - has [...]
Depressive symptoms were assessed in a group of 622 Canadian first-time fathers during their partner’s third trimester using the Edinburgh Postnatal Depression Scale (EPDS). The prevalence of depressive symptoms in fathers was 13.76% at 2 [...]
Twenty years ago, when we started screening for postpartum depression at our hospital, an obstetrics nurse gave the new mother a questionnaire at the mother’s six week visit. If everything went as planned, the mother [...]
